iBody logo — Advancing health and quality of life with innovative monoclo...

iBody

Advancing health and quality of life with innovative monoclonal antibody tech from minimal blood samples to enhance treatment and diagnostics.

Founded 2018 Venture round Total: $250.00M Care Economy, Health Care +1

General Information

Company Name iBody
Founded Year 2018
Industries Care Economy, Health Care, Human Resources
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with iBody. To contact iBody, visit ibody.co.jp.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iBody compare?

A PDF of iBody and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iBody soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iBody

iBody is a promising startup that emerged in 2018 with a mission to revolutionize the field of health and quality of life. Hailing from Nagoya University Graduate School of Life and Agriculture, this innovative venture is making strides in the Care Economy, Health Care, and Human Resources sectors. iBody's pioneering approach involves harnessing monoclonal antibody extraction technology from minimal blood samples, with the goal of enhancing treatment and diagnostic techniques, and advancing life sciences. This breakthrough has the potential to significantly improve human health and quality of life. Notably, iBody secured a remarkable ¥150.00M Venture Round investment on 31 July 2020, with support from esteemed investors such as Nissay Capital, Ogaki Kyoritsu Bank, and Juroku Lease. With such impressive advancements and strong investor backing, iBody is undoubtedly a startup to watch in the evolving landscape of health and life sciences.

Business keywords: Monoclonal antibody technology, Healthcare innovation, Diagnostic techniques, Life sciences, Medical advancements, Healthcare research, Quality of life improvement

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round ¥150.00M 3
Nissay Capital, Ogaki Kyoritsu Bank +1
31 Jul 2020
Seed Round ¥100.00M 1
Nissay Capital
16 May 2018

iBody Alternatives & Competitors

View All Alternatives
iBody vs

Toward a world without a need to ”Fight against breast cancer”

Grant
5 employees
Biotechnology, Care Economy
iBody vs
Avelo
Avelo Switzerland

Making every breath count with breath aerosol diagnostics

Grant
13 employees
Care Economy, Health Care
iBody vs
AbilisHealth
AbilisHealth United States

Tennessee’s largest family-owned provider of home-based healthcare services.

29 employees
Care Economy, Health Care

FAQ About iBody

Advancing health and quality of life with innovative monoclonal antibody tech from minimal blood samples to enhance treatment and diagnostics.
iBody was founded in 2018.
iBody operates in Care Economy, Health Care and Human Resources. Its work centres on Monoclonal antibody technology, Healthcare innovation, Diagnostic techniques and Life sciences.
iBody has completed 2 funding rounds, raising a total of $250.00M. The latest funding stage is Venture round.
Top alternatives and competitors to iBody include Lily MedTech Inc., Avelo, AbilisHealth, FirstWave Clinical Consultancy, TopLine MD Alliance. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iBody and Lily MedTech Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iBody, https://bouncewatch.com/company/ibody, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes